We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+13.51%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$506M
AUM Growth
-$103M
Cap. Flow
-$133M
Cap. Flow %
-26.3%
Top 10 Hldgs %
99.69%
Holding
14
New
–
Increased
–
Reduced
4
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$62.5M
2
ESPR
Esperion Therapeutics
ESPR
+$42M
3
AIMT
Aimmune Therapeutics
AIMT
+$24.2M
4
AGRX
Agile Therapeutics
AGRX
+$2.33M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$1.06M

Sector Composition

Rank Sector Weight
1 Healthcare 68.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$289M 57.19%
3,438,920
-750,000
-18% -$62.5M
AIMT
2
DELISTED
Aimmune Therapeutics
AIMT
$84.7M 16.74%
2,240,000
-750,000
-25% -$24.2M
VRAY
3
DELISTED
ViewRay, Inc.
VRAY
$69.3M 13.69%
7,480,887
– –
ASXC
4
DELISTED
Asensus Surgical, Inc.
ASXC
$19.1M 3.77%
760,719
-34,344
-4% -$1.06M
ENTL
5
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$12.9M 2.55%
528,655
– –
ADMA icon
6
ADMA Biologics
ADMA
$2.03B
$11.6M 2.29%
3,608,171
– –
CDTX
7
DELISTED
Cidara Therapeutics
CDTX
$6.94M 1.37%
51,057
– –
SYRS
8
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.95M 0.98%
50,857
– –
AGRX
9
DELISTED
Agile Therapeutics
AGRX
$3.51M 0.69%
652
-250
-28% -$2.33M
CMRX
10
DELISTED
Chimerix, Inc.
CMRX
$2.19M 0.43%
472,943
– –
PTX
11
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$504K 0.1%
210,000
– –
ESPR
12
DELISTED
Esperion Therapeutics
ESPR
– –
-837,125
Closed -$42M
ZLTQ
13
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
– –
-11,985
Closed –

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Aisling Capital held 14 positions worth $506M, down 17% from $609M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Aisling Capital withdrew a net $133M in Q4 2017, closing 2 positions and reducing 4 holdings. Its most notable exit was Esperion Therapeutics, an estimated $42M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 79% a quarter earlier.

  • Aisling Capital's biggest Q4 2017 reduction was Loxo Oncology, Inc, cutting an estimated $62.5M.
  • Aisling Capital fully exited Esperion Therapeutics in Q4 2017, selling an estimated $42M.
  • Aisling Capital's ten largest holdings make up 100% of its $506M portfolio in Q4 2017.
  • Aisling Capital opened 0 new positions and closed 2 in Q4 2017.
  • Aisling Capital's portfolio value fell 17% quarter-over-quarter to $506M.

Based on Aisling Capital's 13F filing for Q4 2017, filed 7 Feb 2018.